Prostate cancer genetic testing is mainly applied to patients with regional lymph node metastasis and limited high-risk and very high-risk prostate cancer, and familial hereditary prostate cancer. Some studies claim that prostate cancer is a highly hereditary cancer, and it is estimated that about 40%~50% of prostate cancers are related to hereditary factors. Domestic experts’ opinion: It is recommended to consider DNA damage repair gene germline mutation testing (BRCA2, BRCA1, ATM, PALB2, CHEK2, MLH1, MSH2, MSH6, PMS2 and other genes) for those who are at high risk of hereditary prostate cancer and meet any of the following conditions: 1. Known family members carrying pathogenic mutations in the above genes. 2. patients with a clear family history of tumors, patients with multiple malignant tumors in their consanguineous family members, especially if their age at diagnosis is ≤50 years; and patients who have a brother, father, or other family member diagnosed with prostate cancer or died of prostate cancer before age 60 years. 3. have a suspicious or unknown family history and are recommended after evaluation with adequate genetic counseling. 4. tumor tissue testing reveals a pathogenic mutation in one of the genes listed above that has not been germline verified. 5. intraductal carcinoma and ductal adenocarcinoma. 6. high-risk and above, locally progressive and metastatic prostate cancer. In addition, metastatic prostate cancer can be screened by genetic testing; genetic testing is recommended for locally progressive prostate cancer and those whose pathology includes intraductal carcinoma or ductal adenocarcinoma. It is recommended to go to regular hospitals to evaluate the condition and follow the doctor’s instructions to avoid delaying the condition.